phase II study of Erlotinib for non-small cell lung cancer patients with EGFR mutation

phase II study of Erlotinib for non-small cell lung cancer patients with EGFR mutation - Erlotinib PII for EGFR mutation(+) NSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001849

Enrollment

Registered

2009-04-04

Start date

2008-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

erlotinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To diagnosis non-small cell lung cancer by cytology or histology.To have EGFR mutation. To have a majarble tumor. Without active malignancies. Previously treated with chemotherpy.With adequate organ functions.PS of 0 to 2. To get I.C.

Exclusion criteria

Exclusion criteria: Pericardial effusion With subjective symptoms. Superior vena cava syndrome with necessary of emergecy radiation.

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
progression free survival, overall survival, toxicity	—

Countries

Japan

Contacts

Public ContactKohei Motoshima

Second department of Internal Medecine Nagasaki Thoracic Oncology Group

preiland5461@yahoo.co.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026